Eqis Capital Management Inc. bought a new position in shares of The Clorox Company (NYSE:CLX – Get Rating) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 1,686 shares of the company’s stock, valued at approximately $238,000.
Other hedge funds and other institutional investors have also modified their holdings of the company. Carl Stuart Investment Advisor Inc. acquired a new stake in shares of Clorox in the 1st quarter valued at $28,000. Tcwp LLC acquired a new stake in shares of Clorox during the first quarter worth $30,000. Heritage Financial Services LLC acquired a new position in Clorox in the second quarter valued at about $30,000. Curi Wealth Management LLC grew its stake in Clorox by 64.5% in the second quarter. Curi Wealth Management LLC now owns 227 shares of the company’s stock valued at $32,000 after acquiring an additional 89 shares during the period. Finally, Newbridge Financial Services Group Inc. grew its stake in Clorox by 51.9% in the second quarter. Newbridge Financial Services Group Inc. now owns 234 shares of the company’s stock valued at $33,000 after acquiring an additional 80 shares during the period. Institutional investors own 81.69% of the company’s stock.
Clorox Stock Up 1.6 %
NYSE CLX opened at $144.93 on Wednesday. The business has a fifty day moving average price of $138.59 and a two-hundred day moving average price of $141.66. The company has a debt-to-equity ratio of 4.99, a current ratio of 0.88 and a quick ratio of 0.50. The Clorox Company has a fifty-two week low of $120.50 and a fifty-two week high of $186.86. The stock has a market capitalization of $17.88 billion, a PE ratio of 44.46, a PEG ratio of 2.96 and a beta of 0.31.
Clorox Announces Dividend
Wall Street Analysts Forecast Growth
A number of analysts have recently commented on CLX shares. Evercore ISI assumed coverage on Clorox in a report on Monday, October 17th. They issued an “underperform” rating on the stock. Morgan Stanley upped their target price on Clorox from $130.00 to $142.00 and gave the company an “equal weight” rating in a research report on Wednesday, November 2nd. JPMorgan Chase & Co. decreased their target price on Clorox from $129.00 to $126.00 and set an “underweight” rating on the stock in a research report on Thursday, October 13th. StockNews.com began coverage on Clorox in a research report on Wednesday, October 12th. They issued a “hold” rating on the stock. Finally, Barclays upped their target price on Clorox from $93.00 to $101.00 and gave the company an “underweight” rating in a research report on Friday, August 19th. Ten equities research analysts have rated the stock with a sell rating, four have assigned a hold rating and one has given a buy rating to the company’s stock. According to MarketBeat, Clorox currently has a consensus rating of “Reduce” and a consensus price target of $135.08.
Clorox Company Profile
The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.
- Get a free copy of the StockNews.com research report on Clorox (CLX)
- Power Integrations Stock Can Power Your Portfolio
- Don’t Chase Walmart Higher, Wait For Extra Low Prices
- Home Depot Results (and Institutions) Are A Catalyst For Lowe’s?
- Three Penny Stocks Making Big Moves In November
- Agilent Remains In Buy Range Ahead Of Next Week’s Q4 Report
Receive News & Ratings for Clorox Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clorox and related companies with MarketBeat.com's FREE daily email newsletter.